23andMe Holding Co. (ME) said Friday it agreed to pay $400 million for Lemonaid Health Inc., the on-demand platform for accessing medical care and pharmacy services, in a bid to add telemedicine and prescription drug delivery services. The purchase price includes 25% cash and 75% in shares of 23andMe Class A common stock. The company expects to close the deal by the end of the year. 23andMe CEO Anne Wojcicki said the company will combine its business of providing genetic profiles of consumers with giving patients and healthcare providers better information about health risks and treatments."Lemonaid Health's focus on the patient and its philosophy of delivering individualized care fits perfectly with our mission of empowering people to take control of their health," Wojcicki said. Shares of 23andMe are down 9.6% so far in 2021.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.